Chronic indwelling or intermittent bladder catheterization contributes to an increased risk of bladder cancer and related mortality, with the highest risk observed among individuals using catheters for almost 3 years as well as those with bladder calculi, as suggested in a recent study.
High levels of cotinine in the urine of smokers who have undergone resection for non-muscle invasive bladder cancer (NMIBC) could be a sign of cancer recurrence, according to a study from Lebanon presented at EAU21.
Anti-spike (anti-S) immunoglobulin G (IgG) antibody seropositivity rate in patients on active anticancer treatment remains high approximately 4 months after the second dose of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine, although median IgG titres are significantly lower than those in healthy individuals, a recent study has shown.
The anti–PD-L1 immune checkpoint inhibitor atezolizumab confers survival gains in patients with locally advanced or metastatic urothelial carcinoma (mUC) treated with platinum-containing chemotherapy, according to long-term data from the phase III IMvigor211 trial.
Intravesical Bacillus Calmette-Guerin (BCG) therapy has a favourable safety profile and a low incidence of complications among bladder cancer patients, as well as those with multiple comorbidities, a Singapore study has shown. In addition, the number of instillations does not affect the risk of clinically significant complications.
Comprehensive recommendations on coronavirus disease 2019 (COVID-19) for cancer patients have become available following review of guidelines from 63 national/international oncology societies. [Lancet Oncol 2020, doi: 10.1016/S1470-2045(20)30278-3]
Adding the PD-L1 inhibitor avelumab to best supportive care in the maintenance setting yields significant survival benefit compared with best supporting care alone for patients with advanced bladder cancer who have stable disease following first-line platinum-based chemotherapy, an interim analysis of the JAVELIN Bladder 100 study shows.